Anterior Uveitis Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.80 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Anterior Uveitis Treatment Market Analysis
Over the next few years, the market for treatments for anterior uveitis is expected to grow at a CAGR of 5.8%.
The COVID-19 pandemic has disrupted healthcare patterns, as missed visits have led to the potential for significant disease progression in some patients with noninfectious uveitis. Uveitis patients may be at higher risk than the general population of contracting COVID-19 or suffering a more severe course of the virus. As per the article published in March 2021 by the National Library of Medicine, there was an 86% reduction in outpatient treatment for uveitis in spring 2020 compared to the same period in 2019, thereby affecting the market significantly. However, with the increase in vaccination programs, the outpatient departments started operating at full capacity and are expected to grow during the study period. Furthermore, market growth is stabilizing in the current scenario following COVID-19 as global restrictions ease and disease screening services resume.
There has been an increasing prevalence of uveitis across the globe, leading to blindness. An article published in the journal Frontiers in Medicine in September 2021 indicated that non-infectious uveitis is a leading cause of vision loss around the world. The article indicated that the estimated prevalence of non-infectious uveitis in the United States is 121 per 100,000 people every year. Uveitis is a sight-threatening inflammatory disease affecting the uveal layer of the eye. Redness of the eyes, blurring of the vision, the small size of the pupil, and sensitivity to light can be possible symptoms of anterior uveitis, which, if not treated, can result in permanent blindness. As a result, there are ongoing developments in product applications and treatment modalities.
New treatment options for uveitis, such as corticosteroids and anti-inflammatory drugs, are already gaining traction in the market. The growing number of product launches and rising research and development studies are expected to boost market growth. For instance, in May 2021, Oculis S.A. reported positive data from two clinical proof-of-concept Phase 2 trials with OCS-02, its novel, topical anti-TNF alpha antibody fragment candidate, in Dry Eye Disease (DED) and Acute Anterior Uveitis (AAU). With such good results from the studies, the approval process is likely to be easier, which will help the market.
Furthermore, in August 2021, Cipla received final approval from the United States Food and Drug Administration for its abbreviated new drug application for difluprednate ophthalmic emulsion 0.05%. Difluprednate ophthalmic emulsion 0.05% is the generic version of Novartis's Durezol and is used for the treatment of inflammation and pain associated with ocular surgery as well as for the treatment of endogenous anterior uveitis. So, more product approvals meet the growing demand for treatments for anterior uveitis, which boosts the market.
In addition, other factors, such as the growing geriatric population, are also expected to be driving factors in the growth of the market. However, the high cost of medications and the side effects of corticosteroid treatment are expected to stymie market growth.
Anterior Uveitis Treatment Market Trends
This section covers the major market trends shaping the Anterior Uveitis Treatment Market according to our research experts:
The Corticosteroids Segment is Expected to Hold a Major Market Share in the Anterior Uveitis Market.
Corticosteroids are found to dominate the uveitis treatment market as they are first-line therapies for uveitis management and are given systemically or locally, in the form of drops, periocular injections, intravitreal suspensions, or intravitreal implants. They are the most preferred option over biologics; however, researchers are currently exploring biological therapies for the treatment of uveitis. Early on in the course of uveitis, corticosteroids can quickly and effectively stop inflammation. This is the main benefit of corticosteroids.
Corticosteroids are also used in sustained-release treatment, i.e., in ocular implants. It has thus shown significant results in curing the condition, and researchers are also exploring biological therapies to treat anterior uveitis. In addition, corticosteroids and anti-inflammatory drugs are found to be gaining traction in the market.
Moreover, rising research and development studies highlighting the efficacies of treating corticosteroids in noninfectious uveitis are likely to increase their adoption, thus driving the segment. For instance, the study published in January 2022 by the Journal of Ophthalmic Inflammation and Infection stated that corticosteroids are the standard of care treatment for noninfectious uveitis and can be administered topically, regionally, or systemically. They are often used to treat noninfectious uveitis, such as when there is active inflammation inside the eye or uveitic macular edema.
The innovative product launches by key market players all over the world are contributing to market growth. For instance, in February 2022, Alimera Sciences, Inc., a pharmaceutical company, launched ILUVIEN, which contains fluocinolone acetonide, a corticosteroid, for non-infectious posterior uveitis, in Spain through its Ireland-based European subsidiary, Alimera Sciences Europe Limited. Such product launches are likely to boost the growth of the market over the forecast period.
So, because of the above factors, it is likely that the studied market will grow a lot during the study period.
North America is Expected to Hold a Significant Share in the Market and is Expected to do the Same Over the Forecast Period.
Because of the rising prevalence of uveitis disease in the United States, North America dominates the market. There is also an increasing number of key players in the region, which is leading to the high growth of this regional segment. The other factors resulting in the growth of the market are the growing geriatric population, the rising prevalence of uveitis in the region, and increasing investments in research and development by drug manufacturing companies for innovating new treatments such as corticosteroids.
The growing burden of uveitis in the region will boost the demand for its therapeutics, thus driving the market. According to an article published by the Ocular Immunology and Uveitis Foundation in April 2022, uveitis has an estimated prevalence of about 38 cases per 100,000 people and an incidence of 15 cases per 100,000 people. As per the same source, it is estimated that uveitis afflicts 109,000 people in the United States and that 43,000 new cases a year are diagnosed. Thus, the high prevalence of uveitis is expected to boost the growth of the market over the forecast period.
Additionally, product approvals and launches, a rise in investments, and the adoption of key strategies such as partnerships, mergers, acquisitions, and others are expected to drive market growth. Furthermore, R&D studies demonstrating the efficacy of anterior uveitis treatment will drive market growth. For instance, in September 2021, Tarsier Pharma initiated the Phase III trial TRS4VISION by randomizing the first patient for treatment. TRS4VISION is a Phase III randomized, active-controlled, double-masked study to evaluate the safety and efficacy of TRS01 eye drops in the treatment of subjects with active, non-infectious anterior uveitis, including subjects with uveitic glaucoma. Positive results from such studies will ease the approval process of TRS01 and increase its adoption, thus boosting the market.
Thus, the above-mentioned factors are expected to drive market growth in the United States during the study period.
Anterior Uveitis Treatment Industry Overview
The Anterior Uveitis Treatment Market is consolidated and moderately competitive. There has been a presence of a considerable number of companies that are increasingly adopting strategic initiatives such as new product development, mergers and acquisitions, and regional expansion. Major players in the market include Novartis AG, AbbVie Inc., Aciont Inc., Tarsier Pharma Ltd., and Amgen, among others.
Anterior Uveitis Treatment Market Leaders
-
Novartis AG
-
AbbVie Inc.
-
Aciont Inc.
-
Amgen
-
Tarsier Pharma Ltd
*Disclaimer: Major Players sorted in no particular order
Anterior Uveitis Treatment Market News
- March 2022: Bausch + Lomb and Clearside Biomedical launched Xipere (triamcinolone acetonide injectable suspension) for suprachoroidal use for the treatment of macular edema associated with anterior, intermediate, posterior, or pan uveitis in the United States.
- January 2022: Tarsier Pharma, an advanced clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for blinding ocular diseases, launched an education website about the disease uveitic glaucoma at www.uveiticglaucoma.com as a service to the public.
Anterior Uveitis Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Cases of the Uveitis
- 4.2.2 Development of Novel Drugs and Treatments
-
4.3 Market Restraints
- 4.3.1 High Cost Associated with the Medications
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD Million)
-
5.1 By Treatment Type
- 5.1.1 Corticosteroids
- 5.1.2 Cycloplegic Agents
- 5.1.3 Anti-TNF Agents
- 5.1.4 Immunosuppressants
-
5.2 By Distribution Channel
- 5.2.1 Hospitals Pharmacies
- 5.2.2 Retail Pharmacies
- 5.2.3 Others
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 AbbVie Inc.
- 6.1.2 Aldeyra Therapeutics, Inc.
- 6.1.3 Amgen
- 6.1.4 Clearside Biomedical, Inc.
- 6.1.5 Novartis AG
- 6.1.6 Aciont Inc.
- 6.1.7 Bausch & Lomb Incorporated
- 6.1.8 Sirion Therapeutics, Inc.
- 6.1.9 Santen Inc.
- 6.1.10 Tarsier Pharma Ltd.
- 6.1.11 Oculis
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAnterior Uveitis Treatment Industry Segmentation
As per the scope of the report, anterior uveitis is an eye inflammation that involves the middle layer of the eye. Anterior uveitis is the most common form of uveitis and is the most frequent extra-articular manifestation of ankylosing spondylitis (AS) patients. Untreated anterior uveitis results in loss of vision and permanent eye damage that arises with the development of infections such as glaucoma, retinal edema, or cataract. Anterior uveitis can be treated with eye drops containing anti-inflammatory drugs. The Anterior Uveitis Treatment Market is Segmented by Treatment Type (Corticosteroids, Cycloplegic Agents, Anti-TNF Agents, and Immunosuppressants), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Treatment Type | Corticosteroids | |
| Cycloplegic Agents | ||
| Anti-TNF Agents | ||
| Immunosuppressants | ||
| By Distribution Channel | Hospitals Pharmacies | |
| Retail Pharmacies | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Anterior Uveitis Treatment Market Research FAQs
What is the current Global Anterior Uveitis Treatment Market size?
The Global Anterior Uveitis Treatment Market is projected to register a CAGR of 5.80% during the forecast period (2024-2029)
Who are the key players in Global Anterior Uveitis Treatment Market?
Novartis AG, AbbVie Inc., Aciont Inc., Amgen and Tarsier Pharma Ltd are the major companies operating in the Global Anterior Uveitis Treatment Market.
Which is the fastest growing region in Global Anterior Uveitis Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Anterior Uveitis Treatment Market?
In 2024, the North America accounts for the largest market share in Global Anterior Uveitis Treatment Market.
What years does this Global Anterior Uveitis Treatment Market cover?
The report covers the Global Anterior Uveitis Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Anterior Uveitis Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Anterior Uveitis Treatment Industry Report
Statistics for the 2024 Anterior Uveitis Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Anterior Uveitis Treatment analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
